Elivaldogene tavalentivec - bluebird bio

Drug Profile

Elivaldogene tavalentivec - bluebird bio

Alternative Names: Adrenoleucodystrophy gene therapy - bluebird bio; Lenti-D

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genetix Pharmaceuticals; INSERM
  • Developer bluebird bio
  • Class Adrenoleucodystrophy gene therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Adrenoleucodystrophy

Most Recent Events

  • 21 Feb 2018 bluebird bio intends to file MAA with the European Medicines Agency for Adrenoleucodystrophy (cerebral adrenoleukodystrophy) in 2019
  • 04 Oct 2017 Additional efficacy data from the phase III Starbeam trial in Adrenoleucodystrophy released by bluebird bio
  • 26 Jun 2017 Efficacy data from the phase II/III Starbeam trial in Adrenoleucodystrophy released by bluebird bio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top